Crescendo tacks on $5M more for autoimmune disease testing
Crescendo Bioscience, developer of tests that take a closer look at autoimmune and inflammatory diseases affecting joints, has raised $5 million more in a second round of venture funding, bringing its total to $20 million, according to Dow Jones VentureWire. Based in South San Francisco, the company is backed by Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures.
It will use its new money to prep for the launch of its first product. The company has not revealed much about the launch, but it has been working primarily on tests for arthritis.
Next Story: EoPlex bags $3.8M for miniature 3-D structures
Previous Story: Augmented reality does make money — AcrossAir turns profitable, launches bar finder
Companies: Crescendo Bioscience, inv:Kleiner Perkins Caufield & Byers, inv:Mohr Davidow Ventures
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.